講演情報
[OE8-3]当院の前立腺癌患者に対するがん遺伝子パネル検査の実施状況
○坂本 信一1, 金坂 学斗1, 今村 有佑1, 関根 瑞香2, 渡辺 夏未2, 田中 裕子2, 野竹 真未2, 宇津野 恵美2, 市川 智彦1,2 (1.千葉大学大学院 医学研究院 泌尿器科学, 2.千葉大学医学部附属病院遺伝子診療部)
【Objectives】In prostate cancer, the PROfound trial demonstrated the benefit of PARP inhibitor (Olaparib) in metastatic castration-resistant prostate cancer (CRPC) with BRCA mutation-positive, and there is a growing demand for CGP testing. 【Method】Here, we retrospectively examined 14 prostate cancer patients who underwent CGP testing from March 2021 to March 2022 at Chiba University Hospital.【Result】 Of the 14 patients, 11 patients underwent CGP testing by FoundationOne CDx and 3 by FoundationOne Liquid CDx, with a median age of 69 years (range 48－84 years) at CGP testing. The mean duration and the number of therapeutic regimens from the diagnosis of CRPC to the expert panel discussion were 25 months (range 2－142 months) and 2.5 regimens (range 0-8 regimens), respectively. The specimens included 7 tumors that were castration naive and 7 that were castration-resistant (derived from liver, bone, bladder invasion, and liquid biopsy). CGP testing showed no MSI-high cases and no cases of TMB≧10. There were two cases (14.3%) with BRCA2 mutations, both were treated with olaparib. The specimens of these cases were castration naive. There were three cases (21.4%) with AR aberration, and all of these specimens were castration-resistant.【Conclusion】At our hospital, CGP testing in prostate cancer has provided targeted therapy in 2 out of 14 patients. Timing and specimens of CGP testing need to be appropriately considered.